6th Rare and Genetic Kidney Disease DD Summit Revere Hotel Boston Common, Boston

The 6th Rare and Genetic Kidney Disease Drug Development Summit is the industry’s only meeting dedicated exclusively to advancing therapies across IgAN, FSGS, ADPKD, Alport syndrome, C3G, and related renal indications. Bringing together leaders from biopharma, academia, and patient advocacy, this summit spans discovery through commercialization to support smarter, faster decision-making across kidney disease pipelines.

As competition intensifies in rare and genetic kidney disease drug development, companies are under increasing pressure to differentiate assets, generate robust clinical evidence, and accelerate timelines to patients. Accelerated approval pathways have fundamentally reshaped how teams approach target evaluation, surrogate endpoint selection, and trial design within small, heterogeneous patient populations. With more programs progressing into mid- and late-stage development than ever before, the stakes for getting these decisions right have never been higher.